|
Apart from its direct effect on health (such as cardiovascular diseases and diabetes), obesity is increasingly suspected of playing a role in the prognosis of breast cancer and, in particular, its propensity to spread. However, no direct cause and effect relationship had been demonstrated until now. This breakthrough has finally been made through the collaborative work of two teams of researchers from Inserm, CNRS and the Université Paul Sabatier. Their research has made it possible to highlight, both in vitro and in vivo, the presence of adipose cells (known as adipocytes) near breast tumors. These adipocytes have specific biological characteristics. When associated with tumors, they are capable of modifying the characteristics of cancerous cells, making them more aggressive.
The results of this work are published in Cancer Research of 1st April 2011.
Numerous statistical studies have already established a link between obesity and the “aggressiveness” of breast cancer in women, without ever succeeding to explain this phenomenon. In order to find an explanation, the researchers studied the cross-talk between adipose cells and tumor
cells.
The external part of the breast essentially contains fat tissue, mainly composed of adipose cells. Apart from storing/releasing fats, these cells are capable of secreting numerous proteins. The researchers therefore attempted to find out whether these proteins play a role in the development of breast
cancers.
To do so, the teams headed by Philippe Valet at the Institut des Maladies Métaboliques et Cardiovasculaires (Inserm/Université Paul Sabatier) and Catherine Muller at the Institut de Pharmacologie et de Biologie Structurale (CNRS/Université Paul Sabatier) used an original co-culture system between mammary tumor cells and adipocytes. In the presence of tumor cells, the adipocytes exhibit a modification in the secretion of some of their proteins, including inflammatory proteins such as interleukin-6 (IL-6). Adipose cells progressively establish a real interaction with the tumor, which leads to an increase in its “colonization potential” and thus its
aggressiveness.
Indeed, when injecting mice with tumor cells co-cultivated beforehand with adipocytes, the researchers observed that the tumor was more likely to form metastases. A significant factor is that these specific modifications in adipocytes have been observed in human tumors, confirming the importance of the phenomenon. In addition, the researchers observed that the adipocytes near large human tumors, with ganglionic invasion, contained more IL-6. The protein could thus play an important role in the adipocyte-induced spread of breast cancer.
This works shows that adipocytes undoubtedly play an unexpected role in the spread of such tumors. “Our results now demonstrate how adipocytes actively participate in the progression of breast cancer, orchestrated by tumor cells. They suggest that in the case of obesity, the adipocytes associated with breast cancer could be more likely to amplify the ‘aggressive’ effect of tumors”, the researchers say. “This hypothesis still needs to be verified both in mice and humans.”
The study targets the development of specific strategies for overweight patients suffering from the most aggressive cancers. For example, identifying the signals supplied by the adipocytes to stimulate the invasive properties of tumor cells could represent a new lead for treating these
patients.
This work is financially supported by the French National Cancer Institute.
Source
“Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion”,
Béatrice Dirat (1,2,3), Ludivine Bochet (1,2,3), Marta Dabek (1,2), Danièle Daviaud (1,3), Stéphanie Dauvillier (1,2), Bilal Majed (4), Yuan Yuan Wang (1,2,3), Aline Meulle (1,2,3), Bernard Salles (1,2), Sophie Le Gonidec (1,3), Ignacio Garrido (5), Ghislaine Escourrou (6), Philippe Valet (1,3) and Catherine Muller (1,2)
(1) Université de Toulouse, UPS, F-31077 Toulouse, France
(2) CNRS ; Institut de Pharmacologie et de Biologie Structurale F-31077 Toulouse, France
(3) Institut National de la Santé et de la Recherche médicale, INSERM U1048, F-31432 Toulouse, France
(4) Département de Biosatistiques, Institut Curie, 75005, Paris, France et Unité d’Epidémiologie et de Recherche
Clinique, Hôpital d’Arras, 62000 Arras, France.
(5) Département de Chirurgie Oncologique, Institut Claudius Regaud, 31052 Toulouse, France
(6) Service d’Anatomo-Pathologie, Hôpital de Rangueil, 31403 Toulouse, France.
Cancer Research, 1er avril 2011.
http://www.inserm.fr/
(MDN)
|
